yahoo_financeOriginal article
Regeneron (REGN) Secures FDA Priority Review And EMA Acceptance For Cemdisiran
RegulatoryCemdisiranPositive
AI Analysis
Summary
Regeneron has secured FDA Priority Review designation and EMA acceptance for cemdisiran, accelerating the regulatory review pathway for the drug candidate in both US and European markets.
Outcome Details
FDA Priority Review granted; EMA acceptance received
Importance:7/10
Sentiment:
0.70
FDA Priority ReviewEMA AcceptanceRegulatoryCemdisiran
Related Companies
Read the original article
Published by yahoo_finance on July 4, 2026 4:15 PM